Treatment of nausea and emesis during cancer chemotherapy: Discrepancies between antiemetic effect and well-being

Journal of Pain and Symptom Management

Volumn 24, Issue 3, 2002, Pages 345-358

  Börjeson, Sussanne ^a   Hursti, Timo J ^b   Tishelman, Carol ^c   Peterson, Curt ^a   Steineck, Gunnar ^c  

^a LINKÖPING UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Antiemetics; Chemotherapy; Emesis; Nausea; Nursing intervention; Well being

Indexed keywords

BIPERIDEN; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; LORAZEPAM; METOCLOPRAMIDE; ONDANSETRON; PLACEBO; SARCOLYSIN;

ADULT; ANTIEMETIC ACTIVITY; ANXIETY; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; NAUSEA; OVARY CANCER; PAIN; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SYMPTOMATOLOGY; VOMITING; WELLBEING;

DRUG THERAPY; FEMALE; HUMANS; NAUSEA; OVARIAN NEOPLASMS; TREATMENT OUTCOME; VOMITING;

EID: 0036758279     PISSN: 08853924     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0885-3924(02)00543-2     Document Type: Article

References (53)

1. Griffin A.M., Butow P.N., Coates A.S.et al. On the receiving end. V: Patient perceptions of the side effects of cancer chemotherapy in 1993 Ann Oncol. 7:1996;189-195.
2. Lindley C.M., Hirsch J.D., O'Neill C.V.et al. Quality of life consequences of chemotherapy-induced emesis. Qual Life Res. 1:1992;331-340.
3. Osoba D. Current applications of health-related quality-of-life assessment in oncology. Support Care Cancer. 5:1997;100-104.
4. Diener E. Subjective well-being. Psychol Bull. 95:1984;542-575.
5. Andrews F., Robinson J. Measures of subjective well-being. Robinson J., Shaver P., Wrightsman L. Measures of Personality and Social Psychological Attitudes. 1991;61-114 Academic Press, San Diego.
6. Tope D., Ahles T., Silberfarb P. Psycho-oncology: Psychological well-being as one component of quality of life Psychother Psychosom. 60:1993;129-147.
7. Ferrell B.R., Dow K.H., Grant M. Measurement of the quality of life in cancer survivors. Qual Life Res. 4:1995;523-531.
8. Donnelly S., Walsh D. Quality of life assessment in advanced cancer. Palliat Med. 10:1996;275-283.
9. Coates A., Dillenbeck C.F., McNeil D.R.et al. On the receiving end: II. Linear analogue self-assessment (LASA) in evaluation of aspects of the quality of life of cancer patients receiving therapy Eur J Cancer Clin Oncol. 19:1983;1633-1637.
10. Zee B., Pater J., Osoba D. Global health-related quality of life. a direct measurement vs. aggregate scores Qual Life Res. 4:1995;506.
11. Hurny C., Bernhard J., Coates A.et al. Responsiveness of a single-item indicator versus a multi-item scale: Assessment of emotional well-being in an international adjuvant breast cancer trial Medical Care. 34:1996;234-248.
12. Helgason A.R. Prostate Cancer Treatment and Quality of Life - A Three Level Epidemiological Approach. Department of Oncology. Thesis. 1997;Karolinska Institute, Stockholm.
13. Cull A. Cancer-specific quality of life questionnaires: The state of the art in Europe Eur J Cancer. 33:1997;S3-S7.
14. Gough I.R., Furnival C.M., Schilder L., Grove W. Assessment of the quality of life of patients with advanced cancer. Eur J Cancer Clin Oncol. 19:1983;1161-1165.
15. Fürst C.J., Johansson S., Fredrikson M.et al. Control of cisplatin induced emesis - A multidisciplinary intevention strategy. Med Oncol Tumor Pharmacother. 9:1992;81-86.
16. Peterson C., Hursti T.J., Borjeson S.et al. Single high-dose dexamethasone improves the effect of ondansetron on acute chemotherapy-induced nausea and vomiting but impairs the control of delayed symptoms. Support Care Cancer. 4:1996;440-446.
17. Öst L.G. Applied relaxation: Description of a coping technique and review of controlled studies Behav Res Ther. 25:1987;397-409.
18. Gift A.G. Visual analogue scales: Measurement of subjective phenomena Nurs Res. 38:1989;286-288.
19. Antiemetic Subcommittee of the Multinational Association of Support Care Cancer (MASCC). Prevention of chemotherapy- and radiotherapy-induced emesis: Results of the Perugia consensus conference. Ann Oncol 1998;9(8):811-819.
20. Gralla R.J., Osoba D., Kris M.G.et al. Recommendations for the use of antiemetics: Evidence-based, clinical practice guidelines. American Society of Clinical Oncology J Clin Oncol. 17(9):1999;2971-2994.
21. Pisters K.M.W., Kris M.G. Treatment-related nausea and vomiting. Berger A., Portenoy R.K., Weissman D.E. Principles and Practice of Supportive Oncology. 1998;165-177 Lippincott-Raven Publishers, Philadelphia.
22. Pater J., Slamet L., Zee B.et al. Inconsistency of prognostic factors for post-chemotherapy nausea and vomiting. Support Care Cancer. 2:1994;161-166.
23. Grunberg S.M., Boutin N., Ireland A.et al. Impact of nausea/vomiting on quality of life as a visual analogue scale-derived utility score. Support Care Cancer. 4:1996;435-439.
24. Osoba D., Zee B., Warr D.et al. Quality of life studies in chemotherapy-induced emesis. Oncology. 1:1996;92-95.
25. McCorkle R., Benoliel J.Q., Donaldson G.et al. A randomized clinical trial of home nursing care for lung cancer patients. Cancer. 64:1989;1375-1382.
26. Peruselli C., Camporesi E., Colombo A.M.et al. Quality-of-life assessment in a home care program for advanced cancer patients: A study using the Symptom Distress Scale J Pain Symptom Manage. 8:1993;306-311.
27. Wallace C.L., Appleton C. Nursing as the promotion of well-being. the client's experience J Adv Nurs. 22:1995;285-289.
28. Ream E., Richardson A. The role of information in patients' adaptation to chemotherapy and radiotherapy: A review of the literature Eur J Cancer Care. 5:1996;132-138.
29. Devine E.C., Westlake S.K. The effects of psychoeducational care provided to adults with cancer. meta-analysis of 116 studies Oncol Nurs Forum. 22:1995;1369-1381.
30. Buzdar A.U., Esparza L., Natale R.et al. Lorazepam-enhancement of the antiemetic efficacy of dexamethasone and promethazine. A placebo-controlled study. Am J Clin Oncol. 17:1994;417-421.
31. Malik I.A., Khan W.A., Qazilbash M.et al. Clinical efficacy of lorazepam in prophylaxis of anticipatory, acute, and delayed nausea and vomiting induced by high doses of cisplatin. A prospective randomized trial. Am J Clin Oncol. 18:1995;170-175.
32. Laszlo J., Clark R.A., Hanson D.C.et al. Lorazepam in cancer patients treated with cisplatin: A drug having antiemetic, amnesic, and anxiolytic effects J Clin Oncol. 3:1985;864-869.
33. Kris M.G., Gralla R.J., Clark R.A.et al. Consecutive dose-finding trials adding lorazepam to the combination of metoclopramide plus dexamethasone. improved subjective effectiveness over the combination of diphenhydramine plus metoclopramide plus dexamethasone Cancer Treat Rep. 69:1985;1257-1262.
34. Gordon C.J., Pazdur R., Ziccarelli A.et al. Metoclopramide versus metoclopramide and lorazepam. Superiority of combined therapy in the control of cisplatin-induced emesis. Cancer. 63:1989;578-582.
35. Sanger G. The pharmacology of anti-emetic agents. Andrews P.L.R., Sanger G.J. Emesis in Anti-cancer Therapy. Mechanisms and Treatment. 1993;179-210 Chapman & Hall Medical, London.
36. Harrington R.A., Hamilton C.W., Brogden R.N.et al. Metoclopramide. An updated review of its pharmacological properties and clinical use. Drugs. 25:1983;451-494.
37. Fallon M.T., Hanks G.W. Control of common symptoms in advanced cancer. Ann Acad Med Singapore. 23:1994;171-177.
38. Walsh D., Avashia J. Glucocorticoids in clinical oncology. Cleveland Clinic J Med. 59:1992;505-515.
39. Popiela T., Lucchi R., Giongo F. Methylprednisolone as palliative therapy for female terminal cancer patients. The Methylprednisolone Female Preterminal Cancer Study Group. Eur J Cancer Clin Oncol. 25:1989;1823-1829.
40. Robustelli Della Cuna G., Pelligrini A., Piazzi M. Effect of methylprednisolone sodium succinate on quality of life in preterminal cancer patients: A placebo-controlled, multicenter study Eur J Cancer Clin Oncol. 25:1989;1817-1821.
41. Lyles J.N., Burish T.G., Krozely M.G., Oldham R.K. Efficacy of relaxation training and guided imagery in reducing the aversiveness of cancer chemotherapy. J Consult Clin Psychol. 50:1982;509-524.
42. Burish T.G., Carey M.P., Krozely M.G., Greco F.A. Conditioned side effects induced by cancer chemotherapy: Prevention through behavioral treatment J Consult Clin Psychol. 55:1987;42-48.
43. King C. Nonpharmacologic management of chemotherapy-induced nausea and vomiting. Oncol Nurs Forum. 24:1997;41-48.
44. Tonato M., Roila F., Del Favero A. Nausea in anti-cancer therapy: Measurement and mechanisms Andrews P.L.R., Sanger G.J. Emesis in Anti-cancer Therapy. Mechanisms and Treatment. 1993;61-70 Chapman & Hall Medical, London.
45. Love R.R., Leventhal H., Easterling D.V., Nerenz D.R. Side effects and emotional distress during cancer chemotherapy. Cancer. 63:1989;604-612.
46. Roscoe J, Morrow G, Rosenbluth R, et al. Updates from a seven year monitoring study of chemotherapy induced anticipatory and posttreatment nausea and vomiting, 9th International MASCC Symposium Support Care Cancer, St. Gallen, Switzerland, 1997. Vol. 5. Support Care Cancer.
47. Kris M.G., Gralla R.J., Tyson L.B.et al. Controlling delayed vomiting: Double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin J Clin Oncol. 7:1989;108-114.
48. Kris M.G., Tyson L.B., Clark R.A., Gralla R.J. Oral ondansetron for the control of delayed emesis after cisplatin. Report of a phase II study and a review of completed trials to manage delayed emesis. Cancer. 70:1992;1012-1016.
49. Gebbia V., Testa A., Valenza R.et al. Oral granisetron with or without methylprednisolone versus metoclopramide plus methylprednisolone in the management of delayed nausea and vomiting induced by cisplatin-based chemotherapy. A prospective randomized trial. Cancer. 76:1995;1821-1828.
50. The Italian Group for Antiemetic Research. Ondansetron versus metoclopramide, both combined with dexamethasone, in the prevention of cisplatin-induced delayed emesis. The Italian Group for Antiemetic Research. J Clin Oncol 1997;15:124-130.
51. Steineck G., Ahlbom A. A definition of bias founded on the concept of the study base. Epidemiology. 3:1992;477-482.
52. Steineck G., Kass P.H., Ahlbom A. A comprehensive clinical epidemiological theory based on the concept of the source person-time and four distinct study stages. Acta Oncologica. 37(1):1998;15-23.
53. Shparyk J, Ermolajev O. Measuring the cost of antiemetic therapy in Ukraine, 9th International MASCC Symposium Support Care Cancer, St. Gallen, Switzerland, 1997. Vol. 5. Support Care Cancer.